EUVIMEDEUVIMED entdecken
Crossref

The Emerging Therapeutic Landscape of Bullous Pemphigoid: A Systematic Registry‐Based Analysis of Clinical Trials (2015–2025)

Monika Grochowska-Rak iD, Katarzyna Kulig, Arleta Grabowska, Violetta Karlińska-Jonkisz, Marcin Czop iD, Aleksandra Lesiak iD, Paulina Barasińska iD, Marta Matych, Joanna Narbutt iD

International Journal of Dermatology · 09.07.2026

DOI: 10.1111/ijd.70571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, online erschienen am 09.07.2026. Verfasst von Monika Grochowska-Rak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, John Paul II Provincial Hospital, Belchatow, Poland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Uniwersytet Medyczny w Lodzi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, with increasing incidence and substantial morbidity in elderly patients. Recent advances in understanding BP pathogenesis have led to the development of targeted therapies. However, the clinical trial landscape remains fragmented, and a comprehensive overview of emerging therapies is lacking.

Methods

We performed a systematic analysis of interventional clinical trials registered in ClinicalTrials.gov between January 1, 2015, and December 31, 2025. Trials were identified using the condition terms “bullous pemphigoid” or “pemphigoid” and screened manually according to predefined eligibility criteria. Extracted data included trial design, enrollment, interventions, mechanisms of action, and outcome measures. Trials were categorized by therapeutic mechanism, and heterogeneity in endpoint definitions and use of validated instruments was assessed.

Results

Fourteen interventional trials evaluating emerging pharmacological therapies were included. Trial activity increased markedly after 2019, with predominance of industry‐sponsored studies (64.3%). Investigated mechanisms included FcRn inhibition, complement pathway inhibition, type 2 inflammation targeting, interleukin (IL)‐17/IL‐23 axis modulation, CCR3 antagonism, and B‐cell/immunoglobulin E (IgE)‐targeted approaches. Target enrollment ranged from 5 to 200 participants. High rates of trial discontinuation were observed (42.9% terminated or withdrawn), with reported reasons including futility analyses, strategic sponsor decisions, operational challenges, and administrative factors. Substantial heterogeneity in primary endpoints was identified, with only 35.7% of trials explicitly referencing international consensus definitions. Validated instruments such as the Bullous Pemphigoid Disease Area Index (BPDAI) were widely used (85.7%), while quality‐of‐life measures were less frequently incorporated (35.7%).

Conclusions

The BP clinical trial landscape has expanded significantly, reflecting increasing interest in mechanism‐targeted therapies. However, heterogeneity in endpoint definitions and incomplete adoption of validated outcome measures remain key barriers to evidence synthesis. Standardization of clinical trial design and endpoints is essential to facilitate comparison across studies and accelerate therapeutic development in BP. image

Schlagwörter

Stichwörter der Autor:innen

FcRn inhibitorsbiologicsbullous pemphigoidclinical trialscomplement inhibitorsdupilumaboutcome measures

Autor:innen und Institutionen

  • Department of Dermatology, John Paul II Provincial Hospital, Belchatow, Poland.
  • Department of Clinical Genetics, Medical University of Lublin, Lublin, Poland.
  • Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
  • Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland.

ORCID-Profile: Monika Grochowska-Rak, Marcin Czop, Aleksandra Lesiak, Paulina Barasińska, Joanna Narbutt

Förderung

  • Uniwersytet Medyczny w Lodzi

Zitieren

APA

Grochowska-Rak, M., Kulig, K., Grabowska, A., Karlińska-Jonkisz, V., Czop, M., Lesiak, A., Barasińska, P., Matych, M., & Narbutt, J. (2026). The Emerging Therapeutic Landscape of Bullous Pemphigoid: A Systematic Registry‐Based Analysis of Clinical Trials (2015–2025). International Journal of Dermatology. https://doi.org/10.1111/ijd.70571

Vancouver

Grochowska-Rak M, Kulig K, Grabowska A, Karlińska-Jonkisz V, Czop M, Lesiak A, et al. The Emerging Therapeutic Landscape of Bullous Pemphigoid: A Systematic Registry‐Based Analysis of Clinical Trials (2015–2025). International Journal of Dermatology. 2026. doi:10.1111/ijd.70571

BibTeX
@article{GrochowskaRak2026,
  author = {Grochowska-Rak, Monika and Kulig, Katarzyna and Grabowska, Arleta and Karlińska-Jonkisz, Violetta and Czop, Marcin and Lesiak, Aleksandra and Barasińska, Paulina and Matych, Marta and Narbutt, Joanna},
  title = {The Emerging Therapeutic Landscape of Bullous Pemphigoid: A Systematic Registry‐Based Analysis of Clinical Trials (2015–2025)},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70571}
}
Kostenlos starten →